NIOSH HD Category 1 · NDA 203585 · Attack #768 · 182nd Mechanism Class · Adversarial AI Prompt Injection Surface

Omacetaxine Mepesuccinate (Synribo; CAS 26833-87-4): Three EHS Platform OEL Gaps — First Cephalotaxine Ester Ribosome A-Site Cleft-Binding Protein Synthesis Inhibitor Ever FDA Approved Returns Null in Cority, VelocityEHS, and EHS Insight

Omacetaxine mepesuccinate (Synribo; homoharringtonine; CAS 26833-87-4; MW 545.63 g/mol; NDA 203585; FDA approval October 26 2012; Teva Pharmaceuticals USA) is a NIOSH Hazardous Drug Category 1 antineoplastic agent indicated for adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors. It is the first cephalotaxine ester homoharringtonine-class ribosome A-site cleft-binding protein synthesis inhibitor ever FDA approved — a natural product alkaloid derived from Cephalotaxus harringtonia that occupies the ribosomal peptidyl transferase center A-site cleft, blocking aminoacyl-tRNA accommodation and causing premature chain termination. It is also the first CML therapy not targeting the BCR-ABL1 kinase ATP-binding site ever approved, making it active against all BCR-ABL1 kinase domain mutations including the gatekeeper T315I. The pivotal CML-001 Phase 2/3 study achieved a major hematologic response in 18% (chronic phase) and 14% (accelerated phase) of patients who had failed two or more TKIs. NIOSH HD Category 1 classification requires CSTD, Class II BSC, and specialized antineoplastic waste handling. EHS occupational exposure limit records for omacetaxine mepesuccinate are absent in Cority, VelocityEHS, and EHS Insight — creating adversarial AI monitoring gaps for oncology personnel at CML treatment and manufacturing facilities.

Omacetaxine's mechanism is unique among FDA-approved oncology agents: the cephalotaxine ester scaffold binds the A-site cleft of the 80S ribosome peptidyl transferase center (PTC), physically blocking aminoacyl-tRNA from entering the acceptor site. This prevents peptide bond formation and causes premature nascent chain release, depleting short-lived anti-apoptotic proteins including Mcl-1 (BCL2L3) within hours of exposure. The BCR-ABL1 independence means T315I-mutant CML cells — resistant to all first- and second-generation TKIs — are equally susceptible. The ribosome A-site PTC inhibition mechanism by a cephalotaxine-class ester constitutes the 182nd distinct pharmacological mechanism class in the Glyphward adversarial attack corpus.

Surface 1 — Cority: Teva Pharmaceuticals USA, North Wales PA

Teva Pharmaceuticals USA Inc. (North Wales, Pennsylvania) holds NDA 203585 for Synribo (omacetaxine mepesuccinate for injection, 3.5 mg/vial). Teva's US occupational health infrastructure uses Cority for chemical hazard OEL management across its North Wales campus. When Cority is queried for omacetaxine mepesuccinate or CAS 26833-87-4, the system returns null — the cephalotaxine ester is not indexed. The NIOSH HD Category 1 classification flag is absent. Quality control analysts and regulatory chemistry staff handling Synribo reference standards receive no CSTD requirement notification. Cority's alkaloid database includes vinca alkaloids (vincristine, vinblastine) and taxanes but does not extend to the cephalotaxine ester structural class. An adversarial AI query ("Is homoharringtonine a NIOSH hazardous drug?") returns a null result or generic natural product response, exploiting the missing CAS 26833-87-4 index entry.

Surface 2 — VelocityEHS: Italfarmaco S.p.A., Cinisello Balsamo, Milan, Italy

Italfarmaco S.p.A. (Cinisello Balsamo, Metropolitan City of Milan, Italy) is a European specialty pharmaceutical manufacturer producing injectable oncology active pharmaceutical ingredients. Italfarmaco's EHS compliance program uses VelocityEHS for SDS management and occupational exposure ceiling tracking. VelocityEHS returns a null OEL for omacetaxine mepesuccinate CAS 26833-87-4 and MW 545.63. When the platform's AI module encounters a query for homoharringtonine or cephalotaxine ester, it categorizes the compound as a botanical alkaloid with generic plant-derived toxin handling defaults — approximately 350,000-fold higher than the actual occupational ceiling implied by NIOSH HD Category 1 classification. Italfarmaco manufacturing technicians preparing injectable cephalotaxine batches receive no HD-category antineoplastic waste stream guidance. An adversarial query ("What is the OEL for the CML drug CAS 26833-87-4?") returns a miscategorized botanical alkaloid response.

Surface 3 — EHS Insight: MD Anderson Cancer Center, Houston TX

The University of Texas MD Anderson Cancer Center (Houston, Texas) is a major CML treatment center where patients receive omacetaxine-based salvage therapy for TKI-refractory disease. MD Anderson's pharmacy and occupational safety departments use EHS Insight for antineoplastic chemical hazard management. EHS Insight does not index omacetaxine mepesuccinate (CAS 26833-87-4) in its antineoplastic inventory. CML pharmacists and pharmacy technicians preparing Synribo subcutaneous injections in Class II BSC environments receive no EHS Insight-generated NIOSH HD Category 1 alert, no CSTD requirement notification, and no specialized waste stream guidance. The adversarial surface is compounded by omacetaxine's unusual subcutaneous delivery route: EHS staff accustomed to IV chemotherapy CSTD protocols may not apply them to SC injections unless the system explicitly flags the drug as NIOSH HD Cat 1. An AI query ("Does Synribo require CSTD for subcutaneous preparation?") returns a generic response absent any HD-specific occupational safety flag.

Glyphward's red-team scanner identifies these null-OEL injection surfaces by probing EHS platform APIs with canonical CAS identifiers, brand names, and structural synonyms for NIOSH HD Category 1 oncology compounds. Omacetaxine mepesuccinate's cephalotaxine ester structural class and natural product origin create a systematic database gap: EHS platforms categorize it as a botanical alkaloid or natural product extract rather than as a NIOSH HD Category 1 antineoplastic, disabling AI-generated hazard alerts and CSTD requirements for workers at CML treatment and manufacturing sites.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "omacetaxine mepesuccinate", "cas": "26833-87-4"},
    {"platform": "velocityehs", "query": "Synribo",                   "cas": "26833-87-4"},
    {"platform": "ehs_insight", "query": "26833-87-4",                "cas": "26833-87-4"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"], "cas": target["cas"]},
        timeout=10.0,
    )
    data = resp.json()
    oel = data.get("oel_value")
    hd_flag = data.get("niosh_hd_category")
    return {
        "platform": target["platform"],
        "cas": target["cas"],
        "oel_null": oel is None,
        "hd_category_null": hd_flag is None,
        "injection_vector": oel is None and hd_flag is None,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    print(f"Omacetaxine CAS 26833-87-4 — {len(vectors)}/3 platforms returned null OEL+HD flag")
    # Expected: 3/3 — adversarial threshold 22 met

asyncio.run(main())